Merck & Co., Inc. (NYSE:MRK) Shares Sold by Cox Capital Mgt LLC – Notice Today Online

Cox Capital Mgt LLC baritone its wager in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.2% in the 1st quarter, according to the consort in its most past Form 13F filing with the SEC. The concern owned 19,588 shares of the company’s hit after commerce 868 shares during the quarter. Merck & Co., Inc. makes up roughly 1.6% of Cox Capital Mgt LLC’s portfolio, making the hit its 29th maximal position. Cox Capital Mgt LLC’s holdings in Merck & Co., Inc. were worth $2,585,000 as of its most past SEC filing.

A sort of another institutionalised investors and inclose assets hit also fresh added to or baritone their wager in MRK. NTV Asset Management LLC boosted its wager in shares of Merck & Co., Inc. by 0.3% during the 4th quarter. NTV Asset Management LLC today owns 26,534 shares of the company’s hit valued at $2,893,000 after purchase an added 80 shares during the period. SRS Capital Advisors Inc. boosted its function in Merck & Co., Inc. by 1.6% during the ordinal quarter. SRS Capital Advisors Inc. today owns 5,037 shares of the company’s hit valued at $549,000 after purchase an added 81 shares during the terminal quarter. Endowment Wealth Management Inc. grew its wager in Merck & Co., Inc. by 3.2% in the ordinal quarter. Endowment Wealth Management Inc. today owns 2,637 shares of the company’s hit valued at $288,000 after purchase an added 81 shares in the terminal quarter. Onyx Bridge Wealth Group LLC accumulated its function in Merck & Co., Inc. by 0.4% in the 4th quarter. Onyx Bridge Wealth Group LLC today owns 19,166 shares of the company’s hit worth $2,089,000 after purchase an added 83 shares during the terminal quarter. Finally, Pinnacle Holdings LLC accumulated its function in Merck & Co., Inc. by 0.7% in the 4th quarter. Pinnacle Holdings LLC today owns 12,229 shares of the company’s hit worth $1,333,000 after purchase an added 84 shares during the terminal quarter. 76.07% of the hit is owned by inclose assets and another institutionalised investors.

Analysts Set New Price Targets

Several equities analysts fresh weighed in on MRK shares. Cantor interpreter reaffirmed an “overweight” judgement and ordered a $155.00 toll neutral on shares of Merck & Co., Inc. in a investigate inform on Tuesday. author metropolis & Company boosted their direct toll on Merck & Co., Inc. from $130.00 to $135.00 and gave the hit an “equal weight” judgement in a inform on Wednesday, March 27th. Societe Generale downgraded Merck & Co., Inc. from a “hold” judgement to a “sell” judgement and ordered a $104.00 toll direct on the stock. in a inform on Monday, March 11th. Berenberg Bank raised their toll direct on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the consort a “buy” judgement in a investigate inform on Monday, Apr 8th. Finally, TheStreet downgraded shares of Merck & Co., Inc. from a “b+” judgement to a “c+” judgement in a inform on Monday, March 4th. One assets shrink has rated the hit with a delude rating, threesome hit issued a stop rating, octad hit presented a acquire judgement and digit hit appointed a brawny acquire judgement to the stock. Based on accumulation from MarketBeat.com, the hit has a consensus judgement of “Moderate Buy” and an cipher toll direct of $133.00.

View Our Latest Stock Analysis on MRK

Merck & Co., Inc. Stock Up 0.7 %

NYSE MRK unsealed at $130.56 on Friday. The concern has a 50-day ultimate agitated cipher of $128.85 and a 200 punctuation ultimate agitated cipher of $123.25. The consort has a debt-to-equity ratio of 0.77, a hurried ratio of 0.99 and a underway ratio of 1.25. The hit has a mart container of $330.68 billion, a PE ratio of 145.07, a PEG ratio of 2.50 and a beta of 0.39. Merck & Co., Inc. has a dozen punctuation baritone of $99.14 and a dozen punctuation broad of $133.10.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) terminal issued its earnings results on Thursday, Apr 25th. The consort reportable $2.07 EPS for the quarter, fighting analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a convey on justness of 14.05% and a gain edge of 3.76%. The playing had income of $15.78 1000000000 during the quarter, compared to shrink estimates of $15.21 billion. During the aforementioned punctuation in the preceding year, the consort posted $1.40 earnings per share. Merck & Co., Inc.’s income was up 8.9% on a year-over-year basis. On average, investigate analysts prognosticate that Merck & Co., Inc. module place 8.64 EPS for the underway year.

Merck & Co., Inc. Announces Dividend

The concern also fresh declared a quarterly dividend, which module be paying on Monday, July 8th. Investors of achievement on Monday, June 17th module be paying a $0.77 dividend. The ex-dividend fellow is Monday, June 17th. This represents a $3.08 dividend on an annualized foundation and a consent of 2.36%. Merck & Co., Inc.’s payout ratio is currently 342.22%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a aid consort worldwide. It operates finished digit segments, Pharmaceutical and Animal Health. The Pharmaceutical portion offers manlike upbeat caregiver products in the areas of oncology, infirmary accent care, immunology, neuroscience, virology, cardiovascular, and diabetes low the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as substantially as immunogen products consisting of clogging pediatric, adolescent, and grown vaccines low the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, vaccinum 23, and Vaqta names.

Read More

Receive News & Ratings for Merck & Co. Inc. Daily – Enter your telecommunicate come beneath to obtain a apothegmatic regular unofficial of the stylish programme and analysts’ ratings for Merck & Co. Inc. and attendant companies with MarketBeat.com’s FREE regular telecommunicate newsletter.